 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 30-70% |
| Eliminationhalf-life | 5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.054.980 |
| Chemical and physical data | |
| Formula | C20H33N3O4 |
| Molar mass | 379.501 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
Celiprolol is amedication in the class ofbeta blockers, used in the treatment ofhigh blood pressure. It has a unique pharmacology: it is a selectiveβ1 receptorantagonist, but aβ2 receptor partialagonist. It is also a weakα2 receptor antagonist.
It was patented in 1973 and approved for medical use in 1982.[1]
Celiprolol is believed to provide clinical benefit for people with vascularEhlers–Danlos syndrome by promoting normal collagen synthesis in the blood vessels, and by shifting the pressure load away from the vessels most prone to dissection and rupture.[2] In 2019, a new drug application (NDA) for celiprolol was denied by the U.S. Food and Drug Administration (FDA), instead calling for an “adequate and well-controlled” trial to determine whether celiprolol reduced the risk of clinical events in patients with vEDS.[3] In June 2022, Acer Therapeutics Inc. sponsored "Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome (DiSCOVER)".[4]
Brand names include Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm
 | Thisantihypertensive-related article is astub. You can help Wikipedia byexpanding it. |
